CD44 and breast carcinoma: We chose breast cancer cells MDA-MB-231 and SUM159 for this study as both are triple negative breast cancer cells (ER-, PR-, HER2-) with high levels of CD44 expression and contain a subpopulation of cells characterized as TICs [24], [25].